US Dermal Fillers Market - 2025 - 2033

The US dermal fillers market reached US$ 1.7 billion in 2024 and is expected to reach US$ 3.5 billion by 2033, growing at a CAGR of 8.4% during the forecast period 2025-2033.

Dermal Fillers are injectable substances used to restore volume, smooth wrinkles and enhance facial features by filling in areas of the skin that have lost volume or elasticity. They are primarily used in cosmetic procedures to reduce the appearance of fine lines, wrinkles, and facial folds, and to add volume to certain facial features such as the cheeks, lips, and under the eyes. Dermal filler injections are typically performed in outpatient settings, such as dermatology clinics, med spas, or cosmetic surgery centers. The procedure is minimally invasive, and local anesthesia or numbing creams are often used to minimize discomfort. Depending on the type of filler, the procedure usually lasts between 15 to 45 minutes.

The US dermal fillers market has experienced significant growth in recent years, driven by increasing demand for non-surgical aesthetic procedures and advancements in filler technologies. Dermal fillers are generally safe when administered by qualified professionals, but some risks exist, including bruising, swelling, infection, and allergic reactions. Dermal fillers offer huge advantages, thus US regulatory bodies approving the products with clinical evidence.

For instance, in March 2024, the U.S. FDA approved Allergan Aesthetics, (a division of AbbVie) JUVEDERM VOLUMA XC for injection in the temple area to treat moderate to severe temple hollowing in adults over 21. With the best care, the results can last up to 13 months. To balance a patient's overall facial form, JUVEDERM VOLUMA XC temporarily provides volume to the temple, instantly lifting and augmenting its shape, contour, and structure. This creates a seamless transition from the cheekbone to the forehead.

Market Dynamics: Drivers & Restraints

Rising demand for non-surgical aesthetic treatments

The rising demand for non-surgical aesthetic treatments in the United States is significantly driving the growth of the dermal fillers market and is expected to drive the market over the forecast period owing to the increasing preference for minimally invasive procedures, convenience, affordability and immediate results. As consumers increasingly seek non-invasive solutions for aesthetic concerns, dermal fillers have gained popularity due to their ability to provide noticeable results without the need for surgery, long recovery times, or high costs associated with traditional procedures like facelifts.

Dermal fillers typically require little to no downtime, with most patients resuming normal activities within 24 hours. This is highly appealing to individuals with busy lifestyles who cannot afford the long recovery period associated with surgical alternatives. For instance, according to the American Society of Plastic Surgeons (ASPS), non-surgical procedures, including injectables like dermal fillers, saw an increase of 22% in 2020 alone, reflecting a broader trend of growing demand for less invasive treatments.

Advances in filler technologies have contributed to better results and fewer side effects, increasing consumer confidence. These innovations allow for more natural-looking results and longer-lasting effects, with clinical evidence, which has further fueled the popularity of dermal fillers as a go-to non-surgical treatment.

For instance, in June 2024, Evolus, Inc.'s premarket approval (PMA) application for the Evolysse Lift and Evolysse Smooth dermal filler products for the nasolabial fold (NLF) was submitted to the U.S. Food and Drug Administration (FDA). The Evolysse Lift filler is anticipated to be the most popular filler in the product line and will be marketed as the most adaptable for treating facial wrinkles and folds (including NLFs). In place of Evolysse Lift, the Evolysse Smooth filler will be marketed as a gentler formulation option.

High cost associated with dermal fillers

The high cost associated with dermal fillers is a key factor that hampers the growth of the US dermal fillers market. While dermal fillers offer a non-surgical solution for facial rejuvenation, their costs can be prohibitive for a significant portion of the population, limiting accessibility and slowing market expansion. Dermal fillers are not permanent, with results lasting from 6 months to 2 years depending on the type. This means that consumers need to undergo repeat treatments to maintain the effects, leading to additional costs over time.

For instance, according to the American Board of Cosmetic Surgery, the price range of injectable dermal fillers ranges from $540 to $1,680. Formulas like Restylane and Juvederm products typically cost about $500-$600 per syringe. According to the American Society of Plastic Surgeons, the average cost of dermal fillers including hyaluronic acid is $715, the average cost of dermal fillers containing non-hyaluronic acid is $901, and the average cost of lip augmentation using dermal fillers is $743.

Segment Analysis

The US dermal fillers market is segmented based on type, material, application, end-user and region.

Material:

The hyaluronic acid (HA) fillers segment is expected to dominate the dermal fillers market share

Hyaluronic acid (HA) fillers are used for multiple aesthetic purposes, including wrinkle reduction, lip enhancement, under-eye hollows, cheek volume restoration, and nasolabial folds (smile lines). This versatility makes HA fillers the go-to option for both patients and practitioners. For instance, popular brands like Juvederm and Restylane, both of which are based on hyaluronic acid, are used for smoothing out wrinkles, plumping lips, and adding volume to hollow cheeks. These products can be tailored to address different areas of the face with varying gel consistencies and durations.

Hyaluronic acid is a naturally occurring substance in the body, making it highly biocompatible and reducing the risk of adverse reactions. Its safety profile has made it the preferred option for patients who seek effective yet low-risk treatments. The abundance of HA-based filler products, such as Juvederm, Restylane, Belotero, and others, offers consumers a variety of choices for specific needs, such as fine lines, deep wrinkles, or facial volume restoration. This range further drives the segment's growth by catering to different treatment preferences and price points.

For instance, in June 2023, Galderma announced the U.S. Food and Drug Administration (FDA) approval for Restylane Eyelight for the treatment of undereye hollows, also known as dark shadows, in adults over the age of 21. Restylane Eyelight, an undereye hyaluronic acid (HA) dermal filler, is the first and only product in the U.S. formulated with NASHA Technology for volume loss under the eyes, giving patients natural-looking results.

Competitive Landscape

The major players in the US dermal fillers market include AbbVie Inc., Revance Therapeutics, Inc., Tiger Aesthetics Medical, LLC., Galderma SA, Prollenium Medical Technologies, Inc., Teoxane, Merz North America, Inc., AMALIAN, Evolus, Inc. and among others.

Why Purchase the Report?

• Pipeline & Innovations: Reviews ongoing clinical trials, product pipelines, and forecasts upcoming advancements in medical devices and pharmaceuticals.
• Product Performance & Market Positioning: Analyzes product performance, market positioning, and growth potential to optimize strategies.
• Real-World Evidence: Integrates patient feedback and data into product development for improved outcomes.
• Physician Preferences & Health System Impact: Examines healthcare provider behaviors and the impact of health system mergers on adoption strategies.
• Market Updates & Industry Changes: Covers recent regulatory changes, new policies, and emerging technologies.
• Competitive Strategies: Analyzes competitor strategies, market share, and emerging players.
• Pricing & Market Access: Reviews pricing models, reimbursement trends, and market access strategies.
• Market Entry & Expansion: Identifies optimal strategies for entering new markets and partnerships.
• Regional Growth & Investment: Highlights high-growth regions and investment opportunities.
• Supply Chain Optimization: Assesses supply chain risks and distribution strategies for efficient product delivery.
• Sustainability & Regulatory Impact: Focuses on eco-friendly practices and evolving regulations in healthcare.
• Post-market Surveillance: Uses post-market data to enhance product safety and access.
• Pharmacoeconomics & Value-Based Pricing: Analyzes the shift to value-based pricing and data-driven decision-making in R&D.

The US dermal fillers market report delivers a detailed analysis with 39 key tables, more than 36 visually impactful figures, and 129 pages of expert insights, providing a complete view of the market landscape.

Target Audience 2024

• Manufacturers: Pharmaceutical, Medical Device, Biotech Companies, Contract Manufacturers, Distributors, Hospitals.
• Regulatory & Policy: Compliance Officers, Government, Health Economists, Market Access Specialists.
• Technology & Innovation: AI/Robotics Providers, R&D Professionals, Clinical Trial Managers, Pharmacovigilance Experts.
• Investors: Healthcare Investors, Venture Fund Investors, Pharma Marketing & Sales.
• Consulting & Advisory: Healthcare Consultants, Industry Associations, Analysts.
• Supply Chain: Distribution and Supply Chain Managers.
• Consumers & Advocacy: Patients, Advocacy Groups, Insurance Companies.
• Academic & Research: Academic Institutions.